Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Consolidated Net Income rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 11279.92%. This contributed to the annual value of $16.9 million for FY2024, which is 11957.5% up from last year.
  • Gyre Therapeutics' Consolidated Net Income amounted to $5.9 million in Q3 2025, which was up 10784.31% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Consolidated Net Income registered a high of $51.6 million during Q2 2022, and its lowest value of -$101.8 million during Q4 2023.
  • Moreover, its 5-year median value for Consolidated Net Income was $1.6 million (2025), whereas its average is -$7.5 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Consolidated Net Income plummeted by 45319.52% in 2021, and later skyrocketed by 35909.27% in 2022.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Consolidated Net Income stood at -$20.3 million in 2021, then crashed by 41.75% to -$28.8 million in 2022, then crashed by 253.66% to -$101.8 million in 2023, then skyrocketed by 99.57% to -$433000.0 in 2024, then skyrocketed by 1470.9% to $5.9 million in 2025.
  • Its Consolidated Net Income stands at $5.9 million for Q3 2025, versus $1.6 million for Q2 2025 and $3.7 million for Q1 2025.